| Literature DB >> 22264237 |
Liesbet Lodewyckx1, Frédéric Cailotto, Sarah Thysen, Frank P Luyten, Rik J Lories.
Abstract
INTRODUCTION: The aim of this research was to study molecular changes in the articular cartilage and subchondral bone of the tibial plateau from mice deficient in frizzled-related protein (Frzb) compared to wild-type mice by transcriptome analysis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22264237 PMCID: PMC3392806 DOI: 10.1186/ar3695
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Microarray analysis of cartilage and subchondral bone. (A) Frontal hematoxylin-safranin O stained section of the tibia articular cartilage and subchondral bone isolated from a wild-type C57Bl/6 mouse at six weeks of age. Dissected tissues include the articular cartilage (AC), the underlying subchondral bone (SB) containing trabeculae and bone marrow and the upper part of the growth plate (GP). Scale bar = 50 μm (B) Heatmap showing the correlation between the Robust Multiarray Averaging (RMA) expression values for all samples. The three wild-type (WT) and one heterozygous frizzled-related protein (Frzb) (HZ) mouse cluster apart from the two Frzb(KO) mice. Correlations are presented by colors going from green (lowest) to red (highest). (C) Analysis of the representation of genes in the microarray associated with articular cartilage (collagen type 2a1 (Col2a1), collagen type 9a1 (Col9a1), aggrecan, chondromodulin, cartilage oligomeric matrix protein (Comp)), bone (osteopontin, osteocalcin, collagen type 1a1 (Col1a1), bone sialoprotein 2 (Ibsp), tartrate-resistant acid phosphatase type 5 (Acp5)), and hematopoiesis (B-lymphocyte antigen CD20 (Ms4a1), B-cell progenitor kinase (Btk), lymphoid-restricted immunoglobulin octamer-binding protein (Pou2f2), CD3 antigen (CD3), CD8 antigen (CD8), protein tyrosine phosphatase, receptor type C (CD45)). Cartilage- and bone-specific genes were found in the highest percentiles, while T cell, B cell and platelet related genes, were found in lower amounts.
Top 25 differentially up- and down-regulated genes by log fold change (LogFC)
| Up-regulated genes | Down-regulated genes | ||||
|---|---|---|---|---|---|
| D site albumin promoter binding protein | 3.551 | olfactomedin 4 | -4.248 | ||
| phosphoenolpyruvate carboxykinase 1, cytosolic | 2.836 | immunoglobulin kappa chain variable 15-103 | -4.238 | ||
| RNA binding motif protein 45 | 2.689 | apolipoprotein L 11b | -4.151 | ||
| asporin | 2.464 | frizzled-related protein | -3.606 | ||
| angiopoietin-like 7 | 2.461 | matrix metallopeptidase 8 | -3.531 | ||
| HtrA serine peptidase 4 | 2.442 | CD5 antigen-like | -3.442 | ||
| neuronatin | 2.367 | schlafen 1 | -3.388 | ||
| Eph receptor A3 | 2.367 | apolipoprotein L 8 | -3.345 | ||
| LRRN4 C-terminal like | 2.355 | carbonic anhydrase 1 | -3.338 | ||
| angiopoietin-like 1 | 2.344 | glycophorin A | -3.328 | ||
| matrilin 4 | 2.315 | spectrin alpha 1 | -3.294 | ||
| olfactomedin-like 1 | 2.276 | myeloblastosis oncogene | -3.264 | ||
| collagen, type XIV, alpha 1 | 2.260 | erythrocyte protein band 4.2 | -3.245 | ||
| cadherin 13 | 2.230 | carcinoembryonic antigen-related cell adhesion molecule 10 | -3.218 | ||
| collagen, type XIV, alpha 1 | 2.202 | spectrin alpha 1 | -3.175 | ||
| secreted frizzled-related protein 1 | 2.199 | CD177 antigen | -3.173 | ||
| phosphoenolpyruvate carboxykinase 1, cytosolic | 2.189 | immunoglobulin joining chain | -3.158 | ||
| dickkopf homolog 3 ( | 2.166 | glycophorin A | -3.156 | ||
| nuclear receptor subfamily 1, group D, member 2 | 2.142 | Rh blood group, D antigen | -3.152 | ||
| adrenergic receptor, beta 3 | 2.138 | family with sequence similarity 55, member B | -3.151 | ||
| guanine nucleotide binding protein, alpha stimulating | 2.132 | ATP-binding cassette, sub-family A (ABC1), member 13 | -3.142 | ||
| dickkopf homolog 2 ( | 2.131 | myosin light chain kinase 3 | -3.139 | ||
| hemicentin 1 | 2.116 | ankyrin repeat domain 43 | -3.135 | ||
| G protein-coupled receptor 1 | 2.115 | interferon induced transmembrane protein 6 | -3.128 | ||
| leucine rich repeat containing 15 | 2.110 | myeloblastosis oncogene | -3.111 | ||
PANTHER analysis of differentially expressed genes by pathway.
| Pathway | number of genes in reference list | number of regulated genes | Expected number of genes | |
|---|---|---|---|---|
| Integrin signaling pathway | 185 | 19 | 3.48 | 4.78E-09 |
| WNT signaling pathway | 348 | 22 | 6.55 | 1.27E-06 |
| Angiogenesis | 193 | 12 | 3.63 | 3.76E-04 |
| Cadherin signaling pathway | 167 | 11 | 3.14 | 4.07E-04 |
| Alzheimer disease-presenilin pathway | 124 | 9 | 2.33 | 6.84E-04 |
| B cell activation | 87 | 21 | 3.01 | 1.03E-11 |
| p53 pathway | 127 | 18 | 4.39 | 8.32E-07 |
| Inflammation mediated by chemokine and cytokine signaling pathway | 298 | 29 | 10.30 | 1.12E-06 |
| Blood coagulation | 55 | 10 | 1.90 | 2.96E-05 |
| p53 pathway feedback loops 2 | 51 | 9 | 1.76 | 9.15E-05 |
| Parkinson disease | 106 | 13 | 3.66 | 1.13E-04 |
| Cell cycle | 24 | 6 | 0.83 | 2.21E-04 |
| Integrin signaling pathway | 185 | 17 | 6.39 | 3.38E-04 |
| 23 | 5 | 0.79 | 1.36E-03 | |
| DNA replication | 25 | 5 | 0.86 | 1.95E-03 |
| Ras Pathway | 80 | 9 | 2.76 | 2.20E-03 |
| Apoptosis signaling pathway | 141 | 12 | 4.87 | 4.37E-03 |
| T cell activation | 142 | 12 | 4.91 | 4.61E-03 |
| JAK/STAT signaling pathway | 20 | 4 | 0.69 | 5.48E-03 |
| Angiogenesis | 193 | 14 | 6.67 | 8.51E-03 |
| Integrin signaling pathway | 185 | 36 | 9.87 | 7.87E-09 |
| B cell activation | 87 | 24 | 4.64 | 7.10E-09 |
| Inflammation mediated by chemokine and cytokine signaling pathway | 298 | 41 | 15.90 | 2.42E-06 |
| p53 pathway | 127 | 21 | 6.78 | 1.79E-04 |
| Angiogenesis | 193 | 26 | 10.30 | 4.45E-04 |
| Blood coagulation | 55 | 12 | 2.93 | 8.00E-04 |
| p53 pathway feedback loops 2 | 51 | 9 | 2.72 | 2.42E-02 |
| Cell cycle | 24 | 6 | 1.28 | 2.19E-02 |
| WNT signaling pathway | 348 | 31 | 18.57 | 4.57E-02 |
| Axon guidance mediated by netrin | 29 | 6 | 1.55 | 4.36E-02 |
| Parkinson disease | 106 | 13 | 5.66 | 4.22E-02 |
* P-values are obtained by the binomial test; only P-values that fulfilled an additional false discovery rate test are shown.
miRNAs and transcription factors motifs for genes up-regulated in the Frzbmice
| Name/Responsive Element sequence | Description | Enrichment Score | Nominal | FDR* q-value |
|---|---|---|---|---|
| miR-147 | microRNA-147 | 0.49 | 0.000 | 0.172 |
| FoxD1 | forkhead box D1 | 0.48 | 0.000 | 0.027 |
| Znf238 | zinc finger protein 238 | 0.45 | 0.000 | 0.018 |
| Pbx1 | pre B-cell leukemia transcription factor 1 | 0.49 | 0.000 | 0.014 |
| RYTAAWNNNTGAY | No matching TCF | 0.58 | 0.000 | 0.037 |
| AAANWWTGC | No matching TCF | 0.43 | 0.000 | 0.018 |
*False discovery rate (FDR)
Genes linked to WNT signaling that are significantly up- or down-regulated
| Symbol | Name | Function |
|---|---|---|
| actin, alpha 2, smooth muscle, aorta | Target gene | |
| R-spondin 2 homolog ( | Target gene and stimulates WNT/β-catenin pathway | |
| SRY-box containing gene 17 | Target gene | |
| transducin (beta)-like 1X-linked | Target gene and adaptor with the ubiquitin-conjugating/19S proteasome | |
| WNT1 inducible signaling pathway protein 2 | Target gene | |
| dickkopf homolog 2 ( | Extracellular WNT antagonist | |
| dickkopf homolog 3 ( | Extracellular WNT antagonist | |
| naked cuticle 1 homolog ( | Intracellular antagonist | |
| naked cuticle 2 homolog ( | Intracellular antagonist | |
| secreted frizzled-related protein 1 | Extracellular WNT antagonist | |
| secreted frizzled-related protein 2 | Extracellular WNT antagonist | |
| secreted frizzled-related protein 4 | Extracellular WNT antagonist | |
| frizzled homolog 1 ( | WNT receptor | |
| frizzled homolog 2 ( | WNT receptor | |
| frizzled homolog 8 ( | WNT receptor | |
| nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 | Intracellular messenger in non-canonical calcium-dependent pathway | |
| nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 | Intracellular messenger in non-canonical calcium-dependent pathway | |
| prickle homolog 2 ( | Intracellular messenger in non-canonical planar cell polarity pathway | |
| activin A receptor, type I | type I receptor for the TGFβ family | |
| activin A receptor, type IC | type I receptor for the TGFβ family | |
| bone morphogenetic protein receptor, type 1B | type I receptor for the TGFβ family | |
| cadherin 13 | Cell adhesion molecule | |
| dachsous homolog 1 ( | Cell adhesion molecule | |
| protocadherin 9 | Cell adhesion molecule | |
| protocadherin 17 | Cell adhesion molecule | |
| protocadherin 18 | Cell adhesion molecule | |
| protocadherin 19 | Cell adhesion molecule | |
| dickkopf homolog 1 ( | Extracellular WNT antagonist | |
| beta-transducin repeat containing | Stimulates β-catenin ubiquitinilation | |
| beta-arrestin 1 | scaffold in intracellular WNT receptor complex | |
| Beta-arrestin 2 | ||
Figure 2Molecular analysis of the articular cartilage - subchondral bone to corroborate the microarray data. (A) Real-Time PCR analysis of tibia articular cartilage and subchondral bone from frizzled-related protein-knockout (Frzb) mice compared to wild-types. Frzb was virtually absent and secreted frizzled-related protein 1 (Sfrp1) and secreted frizzled-related protein 2 (Sfrp2) were significantly upregulated in Frzbsamples compared to wild-type samples. There was a trend of up-regulation for dickkopf homolog 2 (Dkk2) (one outlier). Data are shown as relative expression values versus hypoxanthine guanine phosphoribosyl transferase (Hprt) (2-ΔCt) (n = four Frzband five wild-type samples; All experiments were performed in duplicate; Mann-Whitney test: P = 0.016 for Frzb, P = 0.032 for Sfrp1, P = 0.016 for Sfrp2 and P = 0.2 for Dkk2). (B-C) Western blot and densitometry analysis of proteins extracted from tibia articular cartilage and subchondral bone showed no consistent change in active (dephospho) β-catenin (80 kDa) (B) and phosphorylated (phospho) Smad 1/5/8 (mothers against decapentaplegic homolog) (55 kDa) (C) between three wild-type (lane 1-3) and in three Frzb(lane 4-6) samples. Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (37 kDa) Western blot is shown as loading control. Quantitative analysis was performed with Image J software. Data are shown as the ratio of the mean optical density (OD) for β-catenin or P-Smad/the mean OD of GAPDH (n = three samples/group; Mann-Whitney test: P > 0.05 for β-catenin and for P-Smad).
Genes related to ECM matrix and cell adhesion
| Symbol | Name | Function |
|---|---|---|
| Collagen alpha-1(III) chain | Fibril forming collagen - co-distributes with type I collagen | |
| Collagen alpha-1(IV) chain | Basal lamina collagen | |
| Collagen alpha-2(IV) chain | Basal lamina collagen | |
| Collagen alpha-4(IV) chain | Basal lamina collagen | |
| Collagen alpha-5(IV) chain | Basal lamina collagen | |
| Collagen alpha-6(IV) chain | Basal lamina collagen | |
| Collagen alpha-1(V) chain | Fibril forming collagen - co-distributes with type I collagen | |
| Collagen alpha-3(V) chain | Fibril forming collagen - co-distributes with type I collagen Type V collagen | |
| Collagen alpha-2(VIII) chain | Basal lamina collagen | |
| Collagen alpha-1(XII) chain | FACIT collagen | |
| Collagen alpha-1(XIV) chain | FACIT collagen | |
| Collagen alpha-1(XVIII) chain | Antiangiogenic factor - pericellular matrix | |
| Collagen alpha-1(XVI) chain | FACIT-collagen | |
| Collagen alpha-1(XVIII) chain | antiangiogenic factor - pericellular matrix | |
| Integrin alpha-8 light chain | RGD-binding integrin | |
| Integrin beta-like protein 1 | Type B like integrin | |
| syndecan 2 | Heparan proteoglycan transmembrane protein | |
| epidermal growth factor receptor | Receptor for epidermal growth factor | |
| insulin-like growth factor 1 | Growth factor stimulating ECM synthesis | |
| platelet derived growth factor receptor alpha chain | Receptor for platelet derived growth factors | |
| vascular endothelial growth factor c | Pro-angiogenic factor - Flt4 ligand | |
| LIM and senescent cell antigen-like-containing domain protein 2 | Focal adhesion molecule | |
| Actin, aortic smooth muscle | ||
| Alpha-parvin | Actin binding protein | |
| Vinculin | Actin binding protein | |
| laminin B1 subunit 1 | Extracellular matrix glycoprotein | |
| laminin, gamma 1 | Extracellular matrix glycoprotein | |
| nephronectin | Ligand for integrin alpha 8/b1 | |
| tenascin N | Extracellular matrix glycoprotein | |
| tenascin XB | Extracellular matrix glycoprotein | |
| thrombospondin 2 | Extracellular matrix glycoprotein | |
| thrombospondin 4 | Extracellular matrix glycoprotein | |
| Integrin alpha-4 | ||
| Integrin alpha-L | ||
| Integrin alpha-M | ||
| Integrin beta-2 | ||
| Integrin beta-2-like protein | ||
| LIM and senescent cell antigen-like-containing domain protein 1 | Focal adhesion molecule | |
| Beta-parvin | Actin binding protein | |
| Mitogen-activated protein kinase kinase kinase 1 | Mitogen activated kinase | |
| Mitogen-activated protein kinase 13 | Mitogen activated kinase | |
| GRB2-related adaptor protein 2 | Adapator protein | |
| Proto-oncogene tyrosine-protein kinase LCK | T cell specific kinase | |
| Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Phosphoinositide 3-kinases | |
| Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Phosphoinositide 3-kinases | |
Figure 3Chondrogenesis after gain or loss of . (A) Real-Time PCR analysis showed increased expression of collagen type 2a1 (Col2a1) and aggrecan in the micro-masses overexpressing frizzled-related protein (FRZB) compared to micro-masses expressing control pcDNA3.1+ vector. Data are shown as the mean of the fold difference compared to the control condition at Day 7 normalised to hypoxanthine guanine phosphoribosyl transferase (Hprt) (2-ΔΔCt) ± SEM (n = six samples/condition; Mann-Whitney test: for aggrecan P = 0.002, P = 0.015 and P = 0.002 and for Col2a1 P = 0.03, P = 0.3 and P = 0.002). (B) Picrosirius Red and Safranin O staining at Day 7 showed increased spreading of collagen fibers and sulphated glycosaminoglycans (GAGs) from the center in micro-masses overexpressing FRZB compared to controls. (C) Protein quantification (optical density (OD) measured at 570 nm) of the micro-masses was comparable between the two groups (n = three samples/group; Mann-Whitney test: P > 0.05). (D) Staining intensity was comparable between FRZB overexpressing micro-masses and controls for Picrosirius Red and significantly decreased for FRZB overexpressing micro-masses for Safranin O staining. Data are shown as the mean OD normalised to the mean protein content (n = three samples/group; Mann-Whitney test: P > 0.05 for Picrosirius Red and P = 0.02 for Safranin O). (E) Real-Time PCR analysis showed decreased expression of Col2a1 and aggrecan in the micro-masses where Frzb was knocked down using the pGIPZ-shRNAmir directed against Frzb compared to controls. Data are shown as the mean of the fold difference compared to the control condition at Day 7 normalised to Hprt (2-ΔΔCt) ± SEM (n = two to three samples for pGIPZ-Ctrl and five to six samples for pGIPZ-FRZB; Mann-Whitney test: for aggrecan P = 0.02 and for Col2a1 P = 0.02). At Day 14 and Day 21 for pGIPZ-Ctrl n = 2 precluding statistical analysis.
Figure 4Minor collagen expression after gain or loss of . (A) Real-Time PCR analysis for collagen type 3α1 (Col3a1) and collagen type 5α1 (Col5a1) expression in the ATDC5 micro-masses overexpressing frizzled-related protein (FRZB) compared to controls at Day 7. Data are shown as the mean fold difference compared to the control condition normalised to hypoxanthine guanine phosphoribosyl transferase (Hprt) (2-ΔΔCt) ± SEM (n = six samples/condition; Mann-Whitney test: for Col3a1 P = 0.24 and for Col5a1 P = 0.06). (B) RT-PCR analysis for Col3a1 and Col5a1 expression in the ATDC5 micro-masses where Frzb was knocked down using the pGIPZ-shRNAmir directed against Frzb compared to controls at Day 7. Data are shown as the mean fold difference compared to the control condition normalised to Hprt (2-ΔΔCt) ± SEM (n = six samples for pGIPZ-Ctrl and three samples for pGIPZ-FRZB; Mann-Whitney test: for Col3a1 P = 0.047 and for Col5a1 P = 0.54). (C) Proliferation assay of ribcage articular chondrocytes isolated from Frzbcompared to wild-type (WT) mice. Data are shown as the difference in fluorescence after 24 h and one week. (n = nine conditions/group; Initial cell densities were 500 (black dots), 2,000 (grey dots) and 4,000 (black circles) cells per well; Mann-Whitney test: P = 0.0019, P = 0.0012 and P = 0.0008).
TCF/LEF responsive elements (RE) in collagen promoters and matching percentage (%)
| TCF/LEF RE sequence |
|
|
|
|---|---|---|---|
| TTCAAAG | 1 × 100% | 1 × 100% | 1 × 85% |
| CTTTGTT | 3 × 85% | 1 × 85% | |
| CCTTTGATC | 3 × 78-80% | 1 × 80% | |
| CCTTTGAT | 3 × 85% | 1 × 87.5% | |
| CCTTTGAA | 3 × 85% | 1 × 87.5% | |
| ATCAAAG | 1 × 85% | 2 × 85% | 1 × 100% |
Genes linked to the cell cycle that are significantly down-regulated
| Symbol | Name | Function |
|---|---|---|
| Cyclin a2 | ||
| Cyclin b1 | ||
| Cyclin b2 | ||
| Cyclin d3 | ||
| Cyclin e1 | ||
| Cyclin e2 | ||
| Cyclin dependent kinase 1 | ||
| Cyclin dependent kinase 2 | ||
| budding uninhibited by benzimidazoles 1 | Kinase in spindle checkpoint function | |
| budding uninhibited by benzimidazoles 1b | Kinase in spindle checkpoint function | |
| CHK1 checkpoint homolog | Checkpoint regulator of cell cycle | |
| CHK2 checkpoint homolog | Checkpoint regulator of cell cycle | |
| mitotic arrest deficient, homolog-like 1 | Mitotic spindle checkpoint | |
| minichromosome maintenance deficient 2 mitotin | Regulator of cell cycle | |
| minichromosome maintenance deficient 4 | Regulator of cell cycle | |
| minichromosome maintenance deficient 5 | Regulator of cell cycle | |
| minichromosome maintenance deficient 6 | Regulator of cell cycle | |
| minichromosome maintenance deficient 7 | Regulator of cell cycle | |
| E2F transcription factor 2 | Regulator of cell cycle | |
| Transcription factor DP1 | Partner of E2F transcription factors | |
| Transcription factor DP1 | Partner of E2F transcription factors | |
| Ttk protein kinase | Mitosis associated kinase | |
| cell division cycle 6 homolog | Regulator of cell cycle | |
| cell division cycle 20 homolog | Regulator of cell cycle | |
| cell division cycle 25a homolog | Regulator of cell cycle | |
| cell division cycle 25b homolog | Regulator of cell cycle | |
| cell division cycle 45 homolog | Regulator of cell cycle | |
| DBF4 homolog ( | Activator of S-phase kinase | |
| extra spindle poles-like 1 | Cleavage of sister chromatids | |
| fizzy/cell division cycle 20 related 1 | Activation of the anaphase promoting complex during mitosis | |
| Growth arrest and DNA damage inducible gene 45a | Regulator of DNA repair and inhibitor of the S phase | |
| origin recognition complex, subunit 1 | Initiation of DNA replication | |
| origin recognition complex, subunit 6 | Initiation of DNA replication | |
| Polo-like kinase 1 | Promoter of mitosis | |
| proliferating cell nuclear antigen | Cofactor of DNA polymerase delta | |
| Retinoblastoma 1 | Regulator of the cell cycle | |
| Retinoblastoma like 1 | Regulator of the cell cycle | |